Revision to Previously Issued Consolidated Financial Statements (Revisions On Previously Issued Consolidated Balance Sheet) (Details) (USD $)	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011		Dec. 31, 2010	Dec. 31, 2009
Assets [Abstract]
Accounts receivable, net	$ 38,109,000		$ 38,465,000	[1]
Inventories	10,424,000		11,141,000	[1]
Deferred tax assets			1,788,000
Total current assets	137,329,000		119,694,000
Goodwill	34,313,000		33,868,000	[2]
Total assets	174,071,000		200,844,000
LIABILITIES AND STOCKHOLDERS' EQUITY [Abstract]
Accrued and other current liabilities	21,427,000		18,357,000	[2]
Total current liabilities	30,812,000		26,449,000
Deferred tax liabilities			8,407,000
Accumulated other comprehensive (loss) income	2,988,000		2,344,000		67,000	22,000
Accumulated deficit	(134,407,000)		(119,196,000)
Total stockholders' equity	143,022,000		150,119,000		82,188,000	57,393,000
Total liabilities and stockholders' equity	174,071,000		200,844,000
Restatement of Accounts Receivable		(1,500,000)	(3,800,000)
Restatement of Inventory		1,300,000	2,300,000
Restatement of goodwill			900,000
Scenario, Previously Reported [Member]
Assets [Abstract]
Accounts receivable, net			42,226,000	[1]
Inventories			8,813,000	[1]
Deferred tax assets			1,732,000
Total current assets			121,071,000
Goodwill			31,973,000	[2]
Total assets			200,326,000
LIABILITIES AND STOCKHOLDERS' EQUITY [Abstract]
Accrued and other current liabilities			17,192,000	[2]
Total current liabilities			25,284,000
Deferred tax liabilities			8,715,000
Accumulated other comprehensive (loss) income			2,341,000
Accumulated deficit			(118,854,000)
Total stockholders' equity			150,458,000
Total liabilities and stockholders' equity			200,326,000
Aggrastat Product Sales [Member] | NovaMed [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY [Abstract]
Restatement of goodwill			1,000,000
Aggrastat Product Sales [Member] | NovaMed [Member] | Restatement Adjustment [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY [Abstract]
Restatement of accrued and other current liabilities			$ 1,000,000

[1] Accounts receivable decreased $3.8 million and inventory increased $2.3 million related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.

[2] Goodwill increased $1.0 million and accrued and other current liabilities increased $1.0 million related to the Company recording a liability for expired product that existed at the time of the NovaMed acquisition, related to pre-acquisition Aggrastat product sales. Goodwill also increased $0.9 million related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.